stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Revenue
Kymera Therapeutics, Inc.'s revenue for fiscal 2025 was $39.2M, down 16.7% from $47.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $105.0M. Over the past ten years it has ranged from $2.9M (fiscal 2019) to $78.6M (fiscal 2023); the current reading is higher than 43% of that period. Kymera Therapeutics, Inc. ranks 93rd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $39.2M | (16.70%) |
| FY2024 | $47.1M | (40.11%) |
| FY2023 | $78.6M | 67.84% |
| FY2022 | $46.8M | (35.71%) |
| FY2021 | $72.8M | 114.00% |
| FY2020 | $34.0M | 1,059.99% |
| FY2019 | $2.9M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $65.0M | 89.15% |
| Mar 2026 | $34.4M | 1,096.97% |
| Dec 2025 | $2.9M | 3.87% |
| Sep 2025 | $2.8M | (75.91%) |
| 23 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | $3.7B |
| TECH Bio-Techne Corp compare | $1.2B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| TGTX TG Therapeutics, Inc. compare | $799.5M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| IBRX ImmunityBio, Inc. compare | $165.8M |
| KYMR Kymera Therapeutics, Inc. | $105.0M |
| SMMT Summit Therapeutics PLC compare | $705.0K |
| PCVX Vaxcyte, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on KYMR
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement